Pertuzumab

SAN ANTONIO — The novel antibody-drug conjugate SHR-A1811 exhibited promising antitumor activity as neoadjuvant treatment for patients with HER2-positive breast cancer, according to data presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — The addition of pyrotinib to first-line trastuzumab and docetaxel improved PFS among patients with HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — A four-therapy combination conferred clinical benefit to nearly all evaluable patients with metastatic triple-positive breast cancer, according to findings of the ASPIRE trial presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — The addition of atezolizumab to chemotherapy, trastuzumab and pertuzumab did not significantly increase pathologic complete response rates among women with HER2-positive breast cancer.

In this episode, menopausal hormone therapy is not associated with breast cancer recurrence and mortality; pandemic-related screening declines may result in ‘increased avoidable cancer deaths’; data on pertuzumab regimen in early breast cancer; and more.

Updated data from a randomized phase 3 study showed a pertuzumab-based regimen continued to provide durable benefit for people with HER2-positive early breast cancer, according to the agent’s manufacturer.

Healio spoke with Amy Tiersten, MD, professor of medicine with Mount Sinai Hospital, about the treatment landscape in HER2-positive breast cancer.

Targeted therapies in HER2-positive breast cancer are integral to the success of treatment outcomes in this patient population.

In this video, Daphna Yael Spiegel, MD, an instructor in radiation oncology at Beth Israel Deaconess Medical Center, spoke with Healio about data from the WSG-ADAPT HER2+/HR– trial presented at ASCO 2021.

Healio spoke with Debu Tripathy, MD, about the use of targeted therapies in breast cancer.